NitroMed, Inc.
Abstracts substantiate positive results of BiDil among blacks with heart failure
Published in Law and Health Weekly, December 17th, 2005
NitroMed, Inc., (NTMD) presented several oral abstracts that feature post-approval analyses of BiDil (isosorbide dinitrate/hydralazine HCI) data from the company's landmark African American Heart Failure Trial (A-HeFT), which further substantiate that the patients taking BiDil had significantly improved survival, prolonged time to hospitalization for heart failure and substantial improvement in patient-reported functional status, versus those patients who received placebo.
The abstracts were presented at the American Heart Association's Scientific Sessions 2005 in Dallas.
BiDil was approved in June of this year by the U.S. Food and Drug...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
More Articles from Law and Health Weekly
- Cooley Godward, LLP
Law firm expands Washington, DC, office and life sciences patent practice - Healthcare Coverage
Cancer treatment systems get 37% boost in reimbursement - Healthcare Coverage
Pharmacy benefits management firm to provide Medicare Part D program - Huazhong University of Science & Technology in Wuhan
Poor quality 3-day old embryos can develop into blastocysts - Information Technology
Regal Medical Group licenses software to automate managed care functions - Kumamoto University
Recent studies add new data to HIV/AIDS vaccines research - More from this issue of Law and Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
